SCHEMBL5402268

SCHEMBL5402268

CNc1nc(Nc2ccccc2)ncc1[N+](=O)[O-]

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 7/20 0.82
GSK3A P49840 6/20 0.67
AURKA O14965 3/20 0.67
PTK2B Q14289 3/20 0.60
MAPT P10636 2/20 0.60
MEN1 O00255 1/20 0.60
CYP1A2 P05177 1/20 0.60
CYP3A4 P08684 1/20 0.60
CYP2C9 P11712 1/20 0.60
CYP2C19 P33261 1/20 0.60
KMT2A Q03164 1/20 0.60
MCL1 Q07820 1/20 0.60
JAK2 O60674 3/20 0.59
LRRK2 Q5S007 1/20 0.59
PIN1 Q13526 1/20 0.59
PLK1 P53350 2/20 0.56
STK17A Q9UEE5 2/20 0.50
ALDH1A1 P00352 2/20 0.49
PTK2 Q05397 4/20 0.49
IGF1R P08069 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5406396 0.92 GSK3B (0.70) GSK3BGSK3AAURKAPTK2BMAPT
SCHEMBL5406400 0.89 GSK3B (0.65) GSK3BGSK3AAURKAPTK2BMAPT
SCHEMBL5419368 0.88 GSK3B (0.63) GSK3BGSK3AAURKAPTK2BMAPT
SCHEMBL5408207 0.86 GSK3B (0.61) GSK3BGSK3AAURKAPTK2BMAPT
SCHEMBL5402419 0.86 MAPT (0.62) GSK3BGSK3AAURKAPTK2BMAPT
SCHEMBL5405521 0.86 GSK3B (0.61) GSK3BGSK3AAURKAPTK2BMAPT
SCHEMBL5408180 0.86 STK17A (0.66) GSK3BGSK3AAURKAPTK2BMAPT
SCHEMBL5419357 0.86 GSK3B (0.61) GSK3BGSK3AAURKAPTK2BMAPT
SCHEMBL5425765 0.86 GSK3B (0.61) GSK3BGSK3AAURKAPTK2BMAPT
SCHEMBL5419878 0.86 GSK3B (0.61) GSK3BGSK3AAURKAPTK2BMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046131-A1 PURINES AS PKC-THETA INHIBITORS N.V. Organon and Pharmacopeia, LLC 2011-02-24 US disclosed
US-7166599-B2 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-01-23 US disclosed
US-20050090486-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-04-28 US disclosed
EP-1453516-A2 NOVEL TRI-SUBSTITUTED PYRIMIDINES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2004-09-08 EP disclosed
US-20030134838-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-07-17 US disclosed
WO-2003032994-A2 NOVEL TRI-SUBSTITUTED PYRIMIDINES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046131-A1 PURINES AS PKC-THETA INHIBITORS PRKCQ, PRKCE, PRKCH GSK3B 98/4885GSK3A 96/4885AURKA 935/4885
US-20030134838-A1 Trisubstituted pyrimidines APP, PSEN1, BACE1 GSK3B 1515/4885GSK3A 1624/4885AURKA 2891/4885
US-20050090486-A1 Trisubstituted pyrimidines APP, BACE1, PSEN1 GSK3B 790/4885GSK3A 1236/4885AURKA 3310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.